Research programme: anti-CD47 antibodies - Tioma Therapeutics

Drug Profile

Research programme: anti-CD47 antibodies - Tioma Therapeutics

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Vasculox
  • Developer Tioma Therapeutics
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Aug 2016 Tioma Therapeutics has intellectual property rights for anti-CD47 antibodies
  • 16 Aug 2016 Vasculox is now called Tioma Therapeutics
  • 20 Jul 2016 Early research in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top